Pathogenesis Grants

Doris Duke Clinical Scientist Development Award

The purpose of the Doris Duke Clinical Scientist Development Award Program is to provide support for
mentored research to junior faculty members with an M.D. or M.D./Ph.D. (physician-scientists) working
in any disease area as they begin their careers as independent clinical researchers.

The early stage of career development, when a researcher is transitioning from working in a mentor’s
laboratory to setting up an independent research program and obtaining grant funding, is a critical
period. It is often more difficult for physician-scientists who are conducting clinical research to make
this transition than it is for other researchers because these individuals typically have to balance the
demands of seeing patients with those of conducting research. Those demands, together with the
complexity of today’s research environment and the pace of progress, make it particularly challenging to
maintain the knowledge base needed to be both a clinician and a researcher. Nevertheless, the role of the
physician-scientist in providing the bridge between the clinic and the laboratory is critical for the timely
translation of basic research findings into therapeutic approaches and for the transfer of clinical
knowledge back to the laboratory.

The 2009 Clinical Scientist Development Awards are being offered to eligible junior faculty members at
a funding level of $135,000 per year for 3 years. It is DDCF’s hope that by providing stable support at a
critical career juncture for physician-scientists, the Clinical Scientist Development Award will
encourage physicians to pursue careers in clinical research.

Definition of Clinical Research
For the purposes of this award program, clinical research is defined as research conducted with human
subjects with direct application to the prevention, diagnosis, treatment, or cure of any human disease.

The Foundation’s definition of clinical research includes:
• Studies on the etiology and pathogenesis of human disease
• Therapeutic interventions
• Clinical trials
• Epidemiological studies
• Disease control research
• Operations and implementation research

Eligibility of Nominee
This program is specifically intended to help physician-scientists make the critical transition from
training to independence as clinical investigators.
It is the responsibility of each institution to ensure that its nominees meet all of the eligibility
requirements. The replacement of nominees will not be permitted.
Applicants must:
• Be a physician-scientist conducting clinical research in any disease area;
• Have received an M.D. or a foreign equivalent from an accredited institution;
• Be working in a U.S. degree-granting institution, but do not have to be a U.S. citizen;
• Have a full-time faculty level position not higher than the Assistant Professor level; and
• Have been appointed to their first full-time faculty level position between January 1, 2004 and
January 1, 2009. (All full-time post-fellowship Instructor level positions will be considered full-time
faculty level appointments).

Online Submission of Nominations
Institutions nominating candidates must submit their nominations using the online system at
http://www.ddcf.org/apps/csda/index.asp on or before 5 pm EST on November 5, 2008. Before entering
the online system, please be sure that you gather all the required information listed in the instructions for
nomination which are available at http://www.ddcf.org/mrp-csda. All of an institution’s nominations
must be entered at the same time. Nominations submitted by other methods will not be accepted. It is the
responsibility of the institutions to ensure that candidates nominated

American Laryngological Association/American Laryngological Voice and Research Education Foundation Award

The purpose of this award is to support basic, translational, or clinical research projects in laryngology,
voice, outcomes, and related subjects.
B. ELIGIBILITY
Candidates for this award should be otolaryngologists who have completed their training at an ACGME
accredited program in otolaryngology - head and neck surgery. The principal investigator should be a
physician faculty member of a recognized department, division, or section of otolaryngology-head and
neck surgery. Previous ALA or AAO-HNS Foundation research grant recipients are eligible to compete for
this grant. However, candidates who have successfully obtained funding from a private or federal funding
agency for the same research are ineligible. Candidates who have applied for support of the same
research from other funding sources, and who are notified of an award from both another agency and
from ALA must choose only one of the awards.
C. CONDITIONS
Research supported by this award should be specifically directed toward the pathogenesis,
pathophysiology, diagnosis, prevention, or treatment of diseases, disorders, or conditions of the larynx
and may be either basic or clinical/translational in approach. While not specifically required, proposals
which aim to introduce new knowledge and methodology from other disciplines to research in laryngology
or neurolaryngology, or which demonstrate collaborative effort with members of other related disciplines
are encouraged. Projects must be designed so as to yield useful information within the period of award,
but priority will be given to projects that are also innovative with promise to develop into new long-range
or expanded research programs capable of attracting funding from other sources. The grant application
must be accompanied by letters of support from the Chair of the candidate’s academic department.
These letters are to indicate a general level of support of the applicant, and to demonstrate the fact that
the Department will make time, space, and other resources accessible for completion of the project.
D. TERMS
1. Amount: $10,000 maximum. The foundation will consider requests to cover travel expenses up to
$1000 for the principal investigator to present his/her results at the ALA annual meeting.
2. Period: 12 months, non-renewable

All applicants must submit a Letter of Intent online no later than midnight Eastern Standard Time
December 15. The letter of intent includes the title of the project, the principal investigator, and an
abstract of the work. This will facilitate planning review requirements.

American Head and Neck Society Alando J. Ballantyne Resident Research Pilot Grant

For the best grant application by a resident in the U.S. or Canada. One year, non-renewable, $10,000, one available annually.

The purpose of this award is to support basic, translational, or clinical research projects in head and neck
oncology. Clinical or translational research studies are strongly encouraged and should be specifically
related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck
neoplastic disease. The Alando J. Ballantyne Resident Research Pilot Grant memorializes Alando J.
Ballantyne, M.D., a giving teacher, dedicated surgeon, and a devoted husband and father.
ELIGIBILITY
This grant is open to resident in U.S. or Canadian training programs. Previous AHNS or AAO-HNS
Foundation research grant recipients are eligible to compete for this grant. However, candidates who
have successfully obtained funding from a private or federal funding agency for the same research are
ineligible. Candidates who have applied for support of the same research from other funding sources, and
who are notified of an award from both another agency and from AHNS must choose only one of the
awards.
CONDITIONS
Research supported by this award should be specifically directed toward the pathogenesis,
pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may be
either basic or clinical/translational in approach. While not specifically required, proposals which aim to
introduce new knowledge and methodology from other disciplines to research in head and neck disease,
or which demonstrate collaborative effort with members of other related disciplines are encouraged.
Projects must be designed so as to yield useful information within the period of award, but priority will be
given to projects that are also innovative with promise to develop into new long-range or expanded
research programs capable of attracting funding from other sources. The grant application must be
accompanied by letters of support from the Chair of the candidate’s academic department and from the
principal scientific advisor or mentor. These letters are to indicate a general level of support of the
applicant, the fact that the Department will make time, space, and other resources accessible for
completion of the project, and that the applicant will have appropriate supervision/support throughout the
period of the grant. Applicants must obtain letters of support/understanding from all key personnel on the
project.
TERMS
1. Amount: $10,000 maximum
2. Period: 12 months, non-renewable

All applicants must submit a Letter of Intent online no later than midnight Eastern Standard Time
December 15. The letter of intent includes the title of the project, the principal investigator, and an
abstract of the work. This will facilitate planning review requirements.

American Head and Neck Society Pilot Grant

Open to Medical Students, residents, PhD, and junior faculty residing in the U.S. and Canada to support basic, translational, or clinical research projects in head and neck oncology. One year, $10,000, one available annually.

The purpose of this award is to support basic, translational, or clinical research projects in head and neck
oncology. Clinical or translational research studies are strongly encouraged and should be specifically
related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck
neoplastic disease.
ELIGIBILITY
Candidates for this award should reside in the U.S. or Canada, be medical students, residents, Ph.D.s or
faculty members at the rank of associate professor or below. Previous AHNS or AAO-HNS Foundation
research grant recipients are eligible to compete for this grant. However, candidates who have
successfully obtained funding from a private or federal funding agency for the same research are
ineligible. Candidates who have applied for support of the same research from other funding sources, and
who are notified of an award from both another agency and from AHNS must choose only one of the
awards.
CONDITIONS
Research supported by this award should be specifically directed toward the pathogenesis,
pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may be
either basic or clinical/translational in approach. While not specifically required, proposals which aim to
introduce new knowledge and methodology from other disciplines to research in head and neck disease,
or which demonstrate collaborative effort with members of other related disciplines are encouraged.
Projects must be designed so as to yield useful information within the period of award, but priority will be
given to projects that are also innovative with promise to develop into new long-range or expanded
research programs capable of attracting funding from other sources.
The grant application must be accompanied by letters of support from the Chair of the candidate’s
academic department and from the principal scientific advisor or mentor. These letters are to indicate a
general level of support of the applicant, the fact that the Department will make time, space, and other
resources accessible for completion of the project, and that the applicant will have appropriate
supervision/support throughout the period of the grant. Applicants must obtain letters of
support/understanding from all key personnel on the project.
TERMS
1. Amount: $10,000 maximum
2. Period: One year, non-renewable

All applicants must submit a Letter of Intent online no later than midnight Eastern Standard Time
December 15. The letter of intent includes the title of the project, the principal investigator, and an
abstract of the work. This will facilitate planning review requirements.

Linus Pauling Institute Prize for Health Research

The Prize is sponsored by the Linus Pauling Institute at Oregon State University. The LPI functions from the basic premise that an optimum diet and a healthy lifestyle are the key to optimum health. LPI's mission is to determine the function and role of vitamins, essential minerals, and phytochemicals in promoting optimum health and preventing and treating disease; and to determine the role of oxidative/nitrative stress and antioxidants in human health and disease. Major areas of research in the Institute encompass cardiovascular diseases, cancer, aging, and neurodegenerative diseases. The goal of LPI's outreach and education program is to help people everywhere achieve a healthy and productive life, full of vitality, with minimal suffering, and free of cancer and other debilitating diseases. For more information, please visit the Institute's website.

Nature: The Prize consists of $50,000 and a medal, and is awarded biennially. The recipient of the inaugural 2001 Prize was Bruce N. Ames from the University of California, Berkeley, and Children's Hospital Oakland Research Institute. The 2003 Prize went to Harvard University's Walter C. Willett, and the 2005 Prize to Paul Talalay from the Johns Hopkins University School of Medicine. Our 2007 prize winner was Mark Levine from the National Institutes of Health.

Purpose: The Prize recognizes innovation and excellence in research relating to the roles of vitamins, essential minerals, and phytochemicals in promoting optimum health and preventing or treating disease; and the roles of oxidative/nitrative stress and antioxidants in human health and disease. The goal is to stimulate innovative research that enhances our knowledge of the role of diet and lifestyle in the primary and secondary prevention of disease; and the role of oxidative/nitrative stress in disease pathology. The Prize also recognizes successful efforts to disseminate and implement knowledge on diet, lifestyle, and health to enhance public health and reduce suffering from disease.

Procedure: The nominator should submit a nomination letter, two supporting letters solicited from his/her colleagues, and the candidate's up-to-date curriculum vita. The candidate's research accomplishments in light of the purpose of the Prize should be amply described in the letters. The awardee must be present to accept the Prize and deliver a talk at LPI's "Diet and Optimum Health" conference. The next conference will be May 13-16, 2009.

Nomination packages should be sent to:

Barbara McVicar
Linus Pauling Institute
Oregon State University
571 Weniger Hall
Corvallis, OR 97331-6512

Complete nomination materials must be received by November 1, 2008.

Expertise Transfer Fellowship

The IARC is offering an Expertise Transfer Fellowship to enable an established investigator to spend normally from six to twelve months in an appropriate host institute in a low- / medium-resource country* in order to transfer knowledge and expertise in a research area relevant for the host country and related to the Agency's programmes: epidemiology, biostatistics, environmental chemical carcinogenesis, cancer etiology and prevention, infection and cancer, molecular cell biology, molecular genetics, molecular pathology and mechanisms of carcinogenesis.

Applications should include a proposed collaborative research project, specifying the link to IARC's on-going activities and a letter of support from the host lab giving details of feasibility and anticipated benefit to the receiving institute. A letter of endorsement from a research Group at IARC must also be provided. Priority will be given to projects directly linked to IARC's on-going research programme, involving at least one contact at IARC.

Applicants should be established cancer researchers actively engaged in the field with appropriate scientific or medical qualifications and an excellent publications' record. They must also belong to the staff of a university or a research institution.
Deadline for receipt of applications is: 30 November 2008

Candidates will be notified of the outcome of their application by the end of April 2009. There will be an annual remuneration of up to US$70,000, which will take into account the on-going salary of the Fellow. This amount may include limited support for the project. The cost of travel will also be met. The Award should be taken up no later than November 2009.

(*any country other than those classified as high-income economies by the World Bank)

Fellowship application forms and more detailed information are available from:

Fellowship Programme
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
150 cours Albert-Thomas, 69372 Lyon Cedex 08, France
Tel: +33 (0)472 73 84 48; Fax: +33 (0)472 73 80 80; E-mail: fel@iarc.fr

Visiting Scientist Award

The IARC is offering a Visiting Scientist Award for a qualified and experienced investigator with recent publications in international peer-reviewed scientific journals who wishes to spend from six to twelve months at the IARC working on a collaborative project in a research area related to the Agency's programmes: epidemiology, biostatistics, environmental chemical carcinogenesis, cancer etiology and prevention, infection and cancer, molecular cell biology, molecular genetics, molecular pathology and mechanisms of carcinogenesis.

Candidates are requested to contact the relevant Scientific Groups in order to set up a collaborative project. For details on scientific programmes and research groups please consult the IARC Web site: http://www.iarc.fr/en/Research-Groups/Clusters-Groups, or contact the IARC at the address below.

Applicants must belong to the staff of a university or a research institution and should provide written assurance of a post to return to at the end of the period of award.
Deadline for receipt of applications is: 30 November 2008

Candidates will be notified of the outcome of their application by the end of April 2009. There will be an annual remuneration of up to US$80,000-, which will take into account the on-going salary of the visiting scientist plus the cost of travel. The Award should be taken up no later than 30 November 2009.

Fellowship application forms and more detailed information are available from:

Fellowship Programme
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC)
150 cours Albert-Thomas, 69008 Lyon, France
Tel: +33 (0)472 73 84 48; Fax: +33 (0)472 73 80 80; E-mail: vsa@iarc.fr

The Eli and Edythe Broad Foundation created the Broad Medical Research Program (BMRP) for Inflammatory Bowel Disease (IBD) Grants in 2001.

IBD refers to two chronic inflammatory gastrointestinal disorders: Crohn's disease and ulcerative colitis. Although numerous scientific advances have been made in understanding and treating IBD, the precise cause, successful treatment and prevention of IBD remain unknown.

The Eli and Edythe Broad Foundation, through the BMRP, provides 40 percent of all private funding for IBD research in the United States. Our approach is different than many traditional scientific and medical funding organizations. We fund early stage investigation – with the goal that innovative ideas need financial support for early testing to ultimately lead to effective treatment, diagnosis and prevention of IBD.

The BMRP provides rapid funding to investigators working in non-profit organizations worldwide for up to two years for basic or clinical IBD research projects that:

* Are innovative
* Are in the early stages of exploration
* Will improve the diagnosis, therapy or prevention of IBD in the near future; and
* Will lead to longer-term funding by more traditional granting agencies

The BMRP provides funding to generate pilot research data, rather than serving as the final grant source for a research project. Grantees are encouraged to generate sufficient preliminary data in the first year in order to compete successfully for continuation funding from us and/or other sources.

A grantee may receive second-year funding from the BMRP if the researcher demonstrates maximal progress in the first year of the grant, validates the original research premise and demonstrates a clear need for additional preliminary data.

Because we believe that great ideas could come from non-traditional sources, we encourage basic and clinical investigators and scientists not currently working in IBD and interdisciplinary teams to apply.

There is a two-step process for requesting funding from the Broad Medical Research Program (BMRP) for Inflammatory Bowel Disease:

1. The first step is to submit a Letter of Interest. Instructions and format for Letters of Interest may be found under “How to Apply.” Decisions on Letters of Interest are based on external expert review of the proposal and usually are made within four to six weeks.

2. If the BMRP is interested in pursuing a project, an invitation is extended to submit a full grant application. At that time, the grant application instructions and forms are sent to the Principal Investigator. Decisions on grant applications are made based on external review by subject experts and usually take eight to 10 weeks.

There are no deadlines or specific dates for applications. Proposals are accepted and reviewed year-round. Revised proposals may only be submitted at the request of the BMRP.

Special Requests for Proposals

The BMRP is currently soliciting proposals in two areas of research:

Differences in IBD incidence between developing and developed countries

The BMRP is funding innovative research into the possible reasons for low and high incidence of IBD in different areas of the globe. Proposals should be exploratory in nature or designed as pilot. The research should shed light on factors that may influence low versus high global areas of prevalence of the disease. The research should ultimately be helpful in improved understanding of the etiology of IBD and the factors that enhance or prevent the genesis of the disease.

IBD and Diabetes Mellitus

The BMRP is interested in early stage exploratory innovative research proposals to investigate the similarities and differences between inflammatory bowel diseases (IBD) and diabetes mellitus (DM).

Proposals should be exploratory in nature designed as pilot projects researching possible commonality in the etiopathogenesis between IBD and DM. Human or animal model studies are welcomed.

How to Apply

Applicants should submit a brief Letter of Interest (up to three pages, not including attachments) as the initial request for funding. Investigators whose Letters of Interest fit the BMRP's criteria and areas of interest will be invited to submit a full grant application.

We recommend you review “Policies” and “Frequently Asked Questions” prior to preparing a Letter of Interest.

Letter of Interest Format

The following information is part of the three-page limit:

* Title of the project
* Specific hypothesis or question to be investigated
* Methodology
* Data analysis
* Anticipated outcomes

The following items (except for #1) are required but not part of the three-page limit:

1. Supportive information, such as references, preliminary data or recent publications, may be included.
2. State why your project fits the BMRP's criteria (see "BMRP Goals"), including its relevance and likely benefits to patients with IBD in the next several years.
3. Attach the investigator’s curriculum vitae(s) or biographical sketch(es).
4. Briefly describe the laboratory or clinical environment.
5. Indicate the estimated total budget (see “Budget” under “Policies”) and the period for which funding is requested. Keep in mind that we are interested in funding exploratory projects in order to test new ideas and directions in IBD research. Thus, funding requests should be in concert with the foundation’s purpose.
6. Provide the principal investigator’s e-mail and postal addresses.

Letter of Interest Submission

1. Direct Letters of Interest to:
Daniel Hollander, M.D.
Director
Broad Medical Research Program
The Eli and Edythe Broad Foundation, Scientific | Medical Research
10900 Wilshire Boulevard, Twelfth Floor
Los Angeles, California 90024-6532
U.S.A.
2. If possible, please send your Letter of Interest and all attachments electronically to: info@broadmedical.org. If you send it electronically, please do not send a printed copy.
3. Receipt of your Letter of Interest will be acknowledged by e-mail within a few days. If you do not hear from us in a timely manner, please contact us at info@broadmedical.org to make sure that your letter has been received.
4. You may include suggestions for potential reviewers and also indicate individuals with potential conflicts of interest.
Unless required by your institution, Letters of Interest may be submitted directly to the BMRP by the Principal Investigator and do not require institutional approval or signature.
5. Letters of Interest are accepted and reviewed throughout the year; there are no deadlines.

Fanconi Anemia Research Fund Program Announcement:
Head And Neck Carcinogenesis 
 
Key Dates
Release Date: July 1, 2008
Application Submission Date: Ongoing
Peer Review Dates: Ongoing
Earliest Anticipated Start Date: Ongoing
Summary
Fanconi anemia is a rare hereditary disease characterized by bone marrow failure, developmental
anomalies, a high incidence of myelodysplasia (MDS) and acute non-lymphocytic leukemia (AML),
squamous cell carcinoma of the head and neck, and cellular hypersensitivity to cross linking agents.
The function of the proteins is largely unknown, but many of them form complexes with each other
and in one canonical “pathway” seven or eight of the known Fanconi anemia (FA) proteins bind
together in a nuclear complex, a complex apparently required for the monoubiquitination of two of
the three proteins not found in the core complex, FANCD2 and FANCI. Once this occurs,
FANCD2 and FANCI translocate to damage-induced nuclear foci containing BRCA1, BRCA2 and
Rad51. The functions of FANCD2 and FANCI in these nuclear complexes are unclear. Although
more than 90% of the research in this field focuses on mechanisms of genotoxicity, a goal of the
Fanconi Anemia Research Fund is to encourage investigative approaches dealing with the tissuespecific
issues of the FA phenotype.
Some have argued that because hypersensitivity to genotoxic stress is a feature of all somatic cells in
FA, tissue-specific outcomes (specific epithelial malignancies and bone marrow failure, for example)
are less likely to be related simply to genetic instability than to other functions of the protein. In fact,
multiple biochemical functions have been ascribed to some of the FA proteins and, in some cases,
these functions are cytoplasmic and not nuclear. The role of the Fanconi anemia proteins in
protecting normal individuals against sporadic head and neck cancers is entirely unknown.
The natural course of the disease in FA patients is unique. The onset of head and neck cancers in
patients with Fanconi anemia (age 18-40) is decades earlier than in non-FA patients with this type of
cancer and, unlike non-FA patients, the majority of such patients are neither tobacco smokers nor
alcohol drinkers. The management of FA patients with this malignancy is also challenging. For
example, FA patients may experience potentially lethal toxic effects from radiation and chemotherapy
doses conventionally prescribed to patients with head and neck cancers. Therefore, clinical
management is limited to surgical approaches and less-than-fully tested pharmacologic modalities
that do not lead to DNA damage.
This funding opportunity will use the investigator-initiated award mechanism to support work
focused on the molecular pathogenesis, diagnosis, and treatment of head and neck squamous cell
carcinoma in patients with FA. We expect that the nature and scope of the proposed research
will vary from application to application. We expect that the size and duration of each award will
also vary. The total amount awarded and the number of awards will depend upon the number,
quality, duration, and costs of the applications received.
Eligible Applications
The goal of this initiative is to foster studies on the molecular pathogenesis, diagnosis and
treatment of head and neck cancers in patients with Fanconi anemia. Applications focusing
primarily on hematopoietic malignancies, bone marrow failure, developmental anomalies,
endocrinopathies, or general functions of the FA proteins in DNA damage and repair responses
will not be accepted for review under this RFA.
Applications from the following will be considered:
􀂃 Eligible domestic and foreign institutions/organizations, including for-profit or nonprofit,
public or private, units of state and local governments, and eligible agencies of the
federal government.
􀂃 Eligible principal investigators include any individual with the skills, knowledge, and
resources necessary to carry out the proposed research.
􀂃 Applicants may submit only one application.
Content and Form of Application Submission
Applications must be prepared using the most current Fanconi Anemia Research Fund (Fund)
research grant application instructions and forms.

Fanconi Anemia Research Fund, Inc.
1801 Willamette Street, Suite 200
Eugene, OR 97401

Telephone: 541-687-4658
Family Support Toll-Free Line (in United States):
1-888-FANCONI (888-326-2664)
Fax: 541-687-0548
E-mail: info@fanconi.org

Dermatopathology Grant
The grant provides financial support for dermatopathology research projects that
benefit the specialty of dermatology.
Applicant Eligibility Requirements:
• M.D.; Ph.D.; M.D., Ph.D.; or D.O. degree
• Dermatologist or pathologist who will have completed a dermatopathology
fellowship in a division or department of dermatology, pathology or
dermatopathology at the time of funding, and is attempting to embark on a
research career. Research proposals may include bench research, classical
epidemiology, outcomes analysis or other approaches and should be clearly
related to advancing the field of dermatopathology
• Investigator in the early stages of career

To meet the application deadline, can my application be postmarked by October 15th?
No. To be considered for a 2009 research award, your complete research application must be
sent so that it is RECEIVED at the Foundation office on or before Wednesday, October 15,
2008. Your application should be sent to the following address:
Medical and Scientific Committee
Dermatology Foundation
1560 Sherman Avenue, Suite 870
Evanston, IL 60201-4808